Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Conditions: Inherited Bone Marrow Failure Syndrome; Familial Platelet Disorder With Predisposition to Myeloid Malignancies Interventions: Drug: imatinib; Device: TruSight Oncology Sponsors: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials